EA202190045A1 - Составы/композиции, содержащие ибрутиниб - Google Patents

Составы/композиции, содержащие ибрутиниб

Info

Publication number
EA202190045A1
EA202190045A1 EA202190045A EA202190045A EA202190045A1 EA 202190045 A1 EA202190045 A1 EA 202190045A1 EA 202190045 A EA202190045 A EA 202190045A EA 202190045 A EA202190045 A EA 202190045A EA 202190045 A1 EA202190045 A1 EA 202190045A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
containing ibrutinib
ibrutinib
compositions containing
methods
Prior art date
Application number
EA202190045A
Other languages
English (en)
Inventor
Маристелла Бернини
Веньуи Дун
Рене Ольм
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA202190045A1 publication Critical patent/EA202190045A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Раскрыты составы/композиции, содержащие ибрутиниба также способы получения таких составов/композиций и способы лечения заболевания или состояния, которые предусматривают применение таких составов/композиций.
EA202190045A 2018-06-15 2019-06-14 Составы/композиции, содержащие ибрутиниб EA202190045A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18177987 2018-06-15
PCT/EP2019/065637 WO2019238904A1 (en) 2018-06-15 2019-06-14 Formulations/compositions comprising ibrutinib

Publications (1)

Publication Number Publication Date
EA202190045A1 true EA202190045A1 (ru) 2021-03-17

Family

ID=62684687

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190045A EA202190045A1 (ru) 2018-06-15 2019-06-14 Составы/композиции, содержащие ибрутиниб

Country Status (13)

Country Link
US (1) US20190381174A1 (ru)
EP (1) EP3806824A1 (ru)
JP (2) JP2021527097A (ru)
KR (1) KR20210021348A (ru)
CN (1) CN112292117A (ru)
AU (1) AU2019287282A1 (ru)
BR (1) BR112020024481A2 (ru)
CA (1) CA3100146A1 (ru)
EA (1) EA202190045A1 (ru)
MA (1) MA52874A (ru)
MX (1) MX2020013684A (ru)
SG (1) SG11202012165WA (ru)
WO (1) WO2019238904A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2755094C1 (ru) * 2020-11-12 2021-09-13 Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Фармасофт" Лекарственная форма для инъекций в виде раствора и стабилизатор для его приготовления

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
AU2005313365A1 (en) * 2004-12-06 2006-06-15 Janssen Pharmaceutica N.V. Oral suspension comprising meloxicam
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
MY187999A (en) 2012-06-04 2021-11-08 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
KR20160066554A (ko) * 2013-10-25 2016-06-10 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
US10314842B2 (en) * 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
WO2015187848A1 (en) * 2014-06-04 2015-12-10 Sampath Deepa Hdac inhibitor and btk inhibitor combinations
CA2955744A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
TW202315634A (zh) 2015-03-03 2023-04-16 美商製藥公司 布魯東氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶抑制劑之醫藥調配物
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
JP6705833B2 (ja) 2015-04-02 2020-06-03 ラティオファルム ゲー・エム・ベー・ハー イブルチニブとカルボン酸との共結晶
HRP20231207T1 (hr) * 2015-04-06 2024-01-19 Janssen Pharmaceutica Nv Pripravak koji sadrži ibrutinib
EP3405178A1 (en) 2016-01-19 2018-11-28 Janssen Pharmaceutica NV Formulations/compositions comprising a btk inhibitor
EA201891440A1 (ru) 2016-01-19 2018-12-28 Янссен Фармацевтика Нв Составы/композиции, содержащие ингибитор btk
CN109640964A (zh) * 2016-05-27 2019-04-16 Tg治疗有限公司 用于治疗B细胞增殖性紊乱的抗-CD20抗体、P13激酶-δ选择性抑制剂和BTK抑制剂的组合

Also Published As

Publication number Publication date
SG11202012165WA (en) 2021-01-28
CA3100146A1 (en) 2019-12-19
MX2020013684A (es) 2021-03-02
CN112292117A (zh) 2021-01-29
KR20210021348A (ko) 2021-02-25
AU2019287282A1 (en) 2020-11-26
MA52874A (fr) 2021-04-21
BR112020024481A2 (pt) 2021-03-02
WO2019238904A1 (en) 2019-12-19
JP2024023262A (ja) 2024-02-21
JP2021527097A (ja) 2021-10-11
US20190381174A1 (en) 2019-12-19
EP3806824A1 (en) 2021-04-21

Similar Documents

Publication Publication Date Title
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201790376A1 (ru) Ингибиторы лизин-специфической деметилазы-1
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA202190073A1 (ru) Композиции и способы лечения видов гемоглобинопатии и талассемии
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201990400A1 (ru) Соединения и композиции и их применение
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
EA201892500A1 (ru) Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
EA201891342A1 (ru) Изоиндольные соединения
ECSP21053104A (es) Moduladores de la expresión de hsd17b13
EA202090414A1 (ru) Соединения и их применение
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.